Page 91, abstract, lines 1-6: The following sentence, which previously read:
Subcutaneous once-daily LY2963016 insulin glargine (LY insulin glargine) [Abasaglar Ò (EU); Basaglar Ò (USA)] has been approved in the EU as a biosimilar to reference insulin glargine (Lantus Ò ), and in the USA as a follow-on biologic to reference insulin glargine, for use in patients with type 1 or 2 diabetes.
should read: Subcutaneous once-daily LY2963016 insulin glargine 100 U/mL (LY insulin glargine) [Abasaglar Ò (EU); Basaglar Ò (USA)] has been approved in the EU as a biosimilar to insulin glargine 100 U/mL (Lantus Ò ) [reference insulin glargine], and in the USA as a follow-on biologic to reference insulin glargine, for use in patients with type 1 or 2 diabetes.
Pages 91-2, section 1, paragraph 1, lines 4-10: The following sentence, which previously read:
Subcutaneous once-daily insulin glargine 100 U/mL (Lantus Ò ) is an established effective and well-tolerated basal insulin therapy in patients with type 1 or 2 diabetes [1] . Following the recent expiration of patents for insulin glargine, biosimilars of insulin glargine developed by other pharmaceutical companies are beginning to enter highly regulated markets [1, 2] .
should read: Subcutaneous once-daily insulin glargine 100 U/mL (Lantus Ò ) [reference insulin glargine] is an established effective and well-tolerated basal insulin therapy in patients with type 1 or 2 diabetes [1] . Following the recent expiration of patents for reference insulin glargine, biosimilars of insulin glargine developed by other pharmaceutical companies are beginning to enter highly regulated markets [1, 2] .
Page 92, section 1, paragraph 2, lines 1-4: The following sentence, which previously read:
Subcutaneous once-daily LY2963016 insulin glargine (LY insulin glargine) 100 U/mL [Abasaglar Ò (EU); Basaglar Ò (USA)] is a long-acting insulin analogue that is biosimilar to reference insulin glargine 100 U/mL.
should read: Subcutaneous once-daily LY2963016 insulin glargine 100 U/mL [Abasaglar Ò (EU); Basaglar Ò (USA)] (LY insulin glargine) is a long-acting insulin analogue that is biosimilar to reference insulin glargine. 
